Belzutifan: Difference between revisions

Revision as of 23:30, 13 August 2021

Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).

Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)^[1]

none

Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs^[2]

Revision as of 23:28, 13 August 2021 (view source) Penarc (talk \| contribs) (→‎ATC) ← Older edit		Revision as of 23:30, 13 August 2021 (view source) Penarc (talk \| contribs) (dutch wikiLink) Newer edit →
Line 16:		Line 16:

	{{wikidata\|Q27456641}}		{{wikidata\|Q27456641}}
			[[nl:Belzutifan]]